Fentanyl–Norfentanyl Concentrations During Transdermal Patch Application: LC–MS-MS Urine Analysis

Urine concentrations of fentanyl and norfentanyl during application of Duragesic transdermal patches.

A study of the urinary concentration of fentanyl (F) and its major metabolite norfentanyl (NF) in chronic pain patients treated with the Duragesic continuous release transdermal patches is presented. These patches are available in 10, 20, 30, and 40 cm(2) sizes releasing 25, 50, 75, and 100 microg/h F, respectively. F is rapidly and extensively metabolized, with NF as the major metabolite. Five...

High through put analysis of MALDI time-of-flight MS/MS and LCMS/MS data

Estimation of Nifedipine in Human Plasma by Lcms/ms

Nifedipine and NifedipineD6, (IS) were extracted from the plasma by precipitation method and then separated on a Reverse phase chromatography using the mobile phase mixture of ammonium acetate and methanol at a flow rate of 1.0 ml/min. The analytes were detected in API 4000 Mass spectrometer in the positive atmospheric pressure chemical Ionization (APCI) mode with multiple reactions monitoring ...

API Heterogeneity in a Multilayered Transdermal Patch

Transdermal patches are a popular route for drug delivery because of the sustained drug levels, low side effects, reduced hepatitic first-pass effect and ease of use, including self– administration. The basic components of any transdermal delivery system include one or more active pharmaceutical ingredient s (APIs) dissolved or dispersed in a reservoir or inert polymer matrix; an outer backing ...

Transdermal Patch of Anti-Diabetic Drug

In the present work, monolithic matrix transdermal systems containing Drug x were prepared using various ratios of the polymer blends of hydroxy propyl methyl cellulose (HPMC) and Eudragit S 100 (ES) with triethyl citrate as a plasticizer. A 32 full factorial design was employed. The concentration of HPMC and ES were used as independent variables, while percentage drug release was selected as d...